When Dizziness Turns Out to Be Leptomeningeal Metastasis While Everything Else Improved — Why the Same Drug Can Work in Bone but Not the Brain, and What to Organize Before the Plan Changes

Dizziness is one word covering several different origins. Lightheadedness only on standing up, spinning vertigo arising from the inner ear's vestibular system, and the vague faintness that comes with anemia, dehydration, or medication all begin in different places. When the symptom does not fit any of these, lasts for days, or arrives together with unsteady walking, double vision, or new hearing or facial changes, the central nervous system is usually checked as well. For someone under cancer treatment, that check includes brain parenchymal metastasis and leptomeningeal metastasis.

The two sound alike but sit in different locations. A parenchymal brain metastasis forms a mass inside brain tissue and tends to produce symptoms matching that area's function, such as limb weakness, speech difficulty, or visual field changes. Leptomeningeal metastasis instead spreads along the thin membranes covering the brain and spinal cord and through the space where cerebrospinal fluid circulates, so it often produces several symptoms at once that no single location explains: headache and nausea, neck stiffness, double vision, hearing loss, dizziness and gait instability, even bladder problems. Evaluation typically involves contrast-enhanced MRI, often of the whole brain and spine together, and when needed a cerebrospinal fluid examination obtained by lumbar puncture.

The most confusing sentence is usually this one: the bones and the primary site improved, but the brain got worse. That is not the same as the disease worsening overall. The central nervous system is protected by the blood-brain barrier, and some drugs cannot reach adequate concentrations behind it, particularly large antibody-based agents and certain cytotoxic chemotherapies. A drug that controls disease elsewhere in the body may therefore lose ground inside the brain. When responses differ by site like this, it is described as a mixed response, and the CNS is sometimes called a sanctuary site for the same reason. The issue is less that the drug failed and more that its route of access differs.

Treatment plans are then usually rebuilt along three axes. The first is radiotherapy: depending on the number and location of lesions, this may be narrowly targeted stereotactic radiosurgery, or whole-brain radiotherapy, or focal treatment to a symptomatic spinal level. The second is changing systemic therapy toward agents with relatively better CNS penetration, or toward options matched to tumor type and genomic testing. The third is symptom control, including steroids to reduce swelling and intracranial pressure, anti-seizure medication when a seizure has occurred, and management of nausea and pain. In selected situations, delivering drug directly into the cerebrospinal fluid space by intrathecal chemotherapy, sometimes through an Ommaya reservoir, is discussed. Which combination fits depends on the pattern of spread, overall condition, and prior treatment.

Before the next appointment, a few things are worth putting on paper. First, a symptom log: whether dizziness appears only with position changes or persists lying down, whether mornings are worse, and which companions show up alongside it, with dates and times. Second, an agreed emergency threshold. A first-ever seizure, a drop in consciousness that makes someone hard to rouse, a sudden severe headache with vomiting, rapidly progressing weakness on one side, or an abrupt change in vision should not wait for the next scheduled visit. Third, written questions: whether the spread is parenchymal or leptomeningeal, which radiotherapy technique and how many sessions, whether the new drug was chosen with CNS access in mind, whether cerebrospinal fluid testing is planned, how and when steroids will be tapered, and when and by what measure response will be judged. Fourth, one page listing all current medications and supplements, since steroids affect blood sugar, sleep, and infection risk and may require adjustments.

In hot weather one more layer overlaps. Dehydration and low blood pressure worsen dizziness on their own, and steroids, analgesics, and antiemetics can add drowsiness and unsteadiness. Roughly tracking urine frequency and color, body weight, and fluid intake helps separate dizziness driven by disease from dizziness driven by general condition. If radiotherapy begins, visits are often scheduled daily, so arranging transport, a companion, and a consistent time slot in advance is practical preparation. A changed plan does not mean the previous treatment was wasted; it usually means the tools are being matched to the site that is responding differently.

This article is general information and does not replace individual diagnosis or care. Symptoms, test results, and treatment choices differ from person to person, so please discuss any decision with your own medical team.